RU2013145310A - DISPYRO-PYRROLIDINE DERIVATIVES - Google Patents
DISPYRO-PYRROLIDINE DERIVATIVES Download PDFInfo
- Publication number
- RU2013145310A RU2013145310A RU2013145310/04A RU2013145310A RU2013145310A RU 2013145310 A RU2013145310 A RU 2013145310A RU 2013145310/04 A RU2013145310/04 A RU 2013145310/04A RU 2013145310 A RU2013145310 A RU 2013145310A RU 2013145310 A RU2013145310 A RU 2013145310A
- Authority
- RU
- Russia
- Prior art keywords
- group
- substituted
- substituents selected
- contain
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
1. Соединение, представленное общей формулой (1), или его соль:где кольцо A представляет собой спиросоединенное 4-6-членное насыщенное углеводородное кольцо, которое может содержать один или несколько заместителей, выбранных из Группы 1, или спиросоединенное 6-членное насыщенное гетероциклическое кольцо, которое может содержать один или несколько заместителей, выбранных из Группы 1;кольцо B представляет собой бензольное кольцо, которое может содержать один или несколько заместителей, выбранных из Группы 2, пиридиновое кольцо, которое может содержать один или несколько заместителей, выбранных из Группы 2, или пиримидиновое кольцо, которое может содержать один или несколько заместителей, выбранных из Группы 2;Rпредставляет собой арильную группу, которая может содержать один или несколько заместителей, выбранных из Группы 3, гетероарильную группу, которая может содержать один или несколько заместителей, выбранных из Группы 3, C-Cциклоалкильную группу, которая может содержать один или несколько заместителей, выбранных из Группы 3, или C-Cциклоалкенильную группу, которая может содержать один или несколько заместителей, выбранных из Группы 3;Rпредставляет собой C-Cалкильную группу, которая может быть замещена одним-тремя атомами галогена или одной-тремя гидроксигруппами, или атом водорода; иRпредставляет собой группу, представленную следующими общими формулами (2), (3) или (4):где в формуле (2)каждый из Rи Rнезависимо представляет собой гидроксигруппу, C-Cалкильную группу или C-Cалкоксигруппу, или Rи Rмогут образовывать вместе с атомами углерода, с которыми группы Rи Rсоответственно связаны, 4-6-членное насыщенное углеводородное к1. The compound represented by general formula (1) or a salt thereof: wherein ring A is a spiro compound 4-6 membered saturated hydrocarbon ring, which may contain one or more substituents selected from Group 1, or a spiro compound 6 membered saturated heterocyclic a ring which may contain one or more substituents selected from Group 1; a ring B is a benzene ring which may contain one or more substituents selected from Group 2, a pyridine ring which may hold one or more substituents selected from Group 2, or a pyrimidine ring that may contain one or more substituents selected from Group 2; R represents an aryl group that may contain one or more substituents selected from Group 3, a heteroaryl group that may contain one or more substituents selected from Group 3, a C-C-cycloalkyl group which may contain one or more substituents selected from Group 3, or a C-C-cycloalkenyl group which may contain there are one or more substituents selected from Group 3; R represents a C-C1-6 alkyl group which may be substituted by one to three halogen atoms or one to three hydroxy groups, or a hydrogen atom; and R 1 represents a group represented by the following general formulas (2), (3) or (4): where in the formula (2) each of R and R independently represents a hydroxy group, a C-C alkyl group or a C-C alkoxy group, or R and R can form together with atoms carbon, to which the R and R groups are respectively associated, a 4-6 membered saturated hydrocarbon
Claims (26)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011-052687 | 2011-03-10 | ||
JP2011052687 | 2011-03-10 | ||
US201161546805P | 2011-10-13 | 2011-10-13 | |
US61/546805 | 2011-10-13 | ||
PCT/JP2012/056066 WO2012121361A1 (en) | 2011-03-10 | 2012-03-09 | Dispiropyrrolidine derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2013145310A true RU2013145310A (en) | 2015-04-20 |
RU2612534C2 RU2612534C2 (en) | 2017-03-09 |
Family
ID=46798312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013145310A RU2612534C2 (en) | 2011-03-10 | 2012-03-09 | Dispiropyrrolidine derivatives |
Country Status (28)
Country | Link |
---|---|
US (3) | US8629133B2 (en) |
EP (1) | EP2684880B1 (en) |
JP (1) | JP5792279B2 (en) |
KR (1) | KR101779644B1 (en) |
CN (2) | CN103635473B (en) |
AU (1) | AU2012226890B2 (en) |
BR (1) | BR112013023175B1 (en) |
CA (1) | CA2829188C (en) |
CO (1) | CO6781539A2 (en) |
DK (1) | DK2684880T3 (en) |
ES (1) | ES2666870T3 (en) |
HR (1) | HRP20180646T1 (en) |
HU (1) | HUE038714T2 (en) |
IL (1) | IL228322A (en) |
LT (1) | LT2684880T (en) |
MX (1) | MX342958B (en) |
MY (1) | MY172862A (en) |
PH (1) | PH12015501860A1 (en) |
PL (1) | PL2684880T3 (en) |
PT (1) | PT2684880T (en) |
RS (1) | RS57158B1 (en) |
RU (1) | RU2612534C2 (en) |
SG (2) | SG10201601802YA (en) |
SI (1) | SI2684880T1 (en) |
TR (1) | TR201807311T4 (en) |
TW (1) | TWI494312B (en) |
WO (1) | WO2012121361A1 (en) |
ZA (1) | ZA201306552B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2743432C2 (en) * | 2016-04-06 | 2021-02-18 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Mdm2 protein destructors |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5649825B2 (en) * | 2007-01-31 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Stabilized p53 peptides and methods of use thereof |
ES2430067T3 (en) | 2007-03-28 | 2013-11-18 | President And Fellows Of Harvard College | Sewn polypeptides |
GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
KR20170058446A (en) | 2010-08-13 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | Peptidomimetic macrocycles |
US8629133B2 (en) * | 2011-03-10 | 2014-01-14 | Daiichi Sankyo Company, Limited | Dispiropyrrolidine derivatives |
SG194873A1 (en) * | 2011-05-11 | 2013-12-30 | Sanofi Sa | Spiro-oxindole mdm2 antagonists |
RU2639523C2 (en) | 2011-10-18 | 2017-12-21 | Эйлерон Терапьютикс, Инк. | Peptidomimetic macrocycles and their application |
CA2862038C (en) | 2012-02-15 | 2021-05-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
CA2864120A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
TWI586668B (en) * | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | Crystals of dispiropyrrolidine derivative |
SG10201703533VA (en) | 2012-11-01 | 2017-06-29 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
JP6526563B2 (en) | 2012-11-01 | 2019-06-05 | エイルロン セラピューティクス,インコーポレイテッド | Disubstituted amino acids and methods for their preparation and use |
RU2690663C2 (en) | 2012-12-20 | 2019-06-05 | Мерк Шарп И Доум Корп. | Substituted imidazopyridines as hdm2 inhibitors |
TWI635089B (en) * | 2013-09-04 | 2018-09-11 | 第一三共股份有限公司 | Manufacturing methods of spirooxindole derivatives |
CA2942386A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
US9745292B2 (en) | 2014-03-13 | 2017-08-29 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
AU2015247646B2 (en) * | 2014-04-17 | 2019-06-06 | The Regents Of The University Of Michigan | MDM2 inhibitors and therapeutic methods using the same |
CA2947418A1 (en) * | 2014-04-30 | 2015-11-05 | Incyte Corporation | Processes of preparing a jak1 inhibitor and new forms thereto |
EP3154982B1 (en) | 2014-06-12 | 2018-05-02 | Adamed sp. z o.o. | Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction |
EP3157917B1 (en) | 2014-06-19 | 2020-03-18 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
WO2016001376A1 (en) | 2014-07-03 | 2016-01-07 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
WO2016028391A2 (en) | 2014-08-18 | 2016-02-25 | Hudson Biopharma Inc. | Spiropyrrolidines as mdm2 inhibitors |
MX2017003797A (en) | 2014-09-24 | 2017-06-15 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof. |
CA2961029A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
JP2017532959A (en) * | 2014-10-09 | 2017-11-09 | 第一三共株式会社 | Algorithm for predictors based on gene signature of susceptibility to MDM2 inhibitors |
US10738011B2 (en) | 2014-12-23 | 2020-08-11 | Proteostasis Therapeutics, Inc. | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
MA41253A (en) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR |
US10344023B2 (en) | 2014-12-23 | 2019-07-09 | Proteostasis Therapeutics, Inc. | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
CA2971850A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
TWI711452B (en) * | 2015-02-20 | 2020-12-01 | 日商第一三共股份有限公司 | Combination therapy for cancer |
CN107614003A (en) | 2015-03-20 | 2018-01-19 | 艾瑞朗医疗公司 | Peptidomimetic macrocyclic compound and application thereof |
EP3284466A4 (en) * | 2015-04-13 | 2018-12-05 | Daiichi Sankyo Company, Limited | Treatment method combining mdm2 inhibitor and btk inhibitor |
SI3297438T1 (en) | 2015-05-21 | 2022-03-31 | Chemocentryx, Inc. | Ccr2 modulators |
US10548878B2 (en) | 2015-07-24 | 2020-02-04 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods of increasing CFTR activity |
US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
WO2017062581A1 (en) | 2015-10-06 | 2017-04-13 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating cftr |
PE20181205A1 (en) | 2015-10-09 | 2018-07-23 | Boehringer Ingelheim Int | NEW SPIRO COMPOUNDS [3H-INDOL-3,2'-PYRROLIDIN] -2 (1H) -ONE AND DERIVATIVES AS INHIBITORS OF MDM2-P53 |
EP3364966A1 (en) * | 2015-10-23 | 2018-08-29 | Daiichi Sankyo Company, Limited | Pharmaceutical composition for use in treating aml and method of treating aml in a subject in need thereof |
KR20180064540A (en) | 2015-10-23 | 2018-06-14 | 다이이찌 산쿄 가부시키가이샤 | MDM2 Inhibitor Therapy for Cancer Treatment |
CN105693738A (en) * | 2016-01-14 | 2016-06-22 | 绍兴文理学院 | 3'-phenyl spirono[indoline-3, 2'-pyrrolidine]-2-ketone derivative and preparation method and application thereof |
GB201603779D0 (en) * | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
US9486444B1 (en) | 2016-03-21 | 2016-11-08 | King Saud University | Anti-cancer compound |
CN109563047A (en) | 2016-04-07 | 2019-04-02 | 蛋白质平衡治疗股份有限公司 | Containing silicon atom according to cutting down Kato analog |
PL3458101T3 (en) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Protac antibody conjugates and methods of use |
MA45397A (en) | 2016-06-21 | 2019-04-24 | Proteostasis Therapeutics Inc | COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR |
JPWO2018074387A1 (en) * | 2016-10-17 | 2019-08-08 | 第一三共株式会社 | Combination therapy with MDM2 inhibitor and DNA methyltransferase inhibitor |
GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
CR20200054A (en) | 2017-08-09 | 2020-03-21 | Denali Therapeutics Inc | Compounds, compositions and methods |
JP7382308B2 (en) * | 2017-09-01 | 2023-11-16 | デナリ セラピューティクス インコーポレイテッド | Compounds, compositions and methods |
KR102616949B1 (en) | 2017-09-14 | 2023-12-22 | 다이이찌 산쿄 가부시키가이샤 | Compounds with a cyclic structure |
CA3075638A1 (en) | 2017-09-25 | 2019-03-28 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
WO2019136368A2 (en) | 2018-01-08 | 2019-07-11 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
EP3511334A1 (en) * | 2018-01-16 | 2019-07-17 | Adamed sp. z o.o. | 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53 |
JP2021519775A (en) | 2018-03-30 | 2021-08-12 | インサイト・コーポレイションIncyte Corporation | Treatment of hidradenitis suppurativa with JAK inhibitors |
CN108864113B (en) * | 2018-08-03 | 2021-08-13 | 南方科技大学 | MDM2-HDAC double-target inhibitor, pharmaceutical composition, preparation and application thereof |
TWI837231B (en) | 2018-11-29 | 2024-04-01 | 日商第一三共股份有限公司 | Pharmaceutical combination containing ezh1/2 dual inhibitor and use thereof |
CA3129609A1 (en) | 2019-02-13 | 2020-08-20 | Denali Therapeutics Inc. | Eukaryotic initiation factor 2b modulators |
WO2020181247A1 (en) * | 2019-03-06 | 2020-09-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
WO2020238791A1 (en) * | 2019-05-24 | 2020-12-03 | 江苏恒瑞医药股份有限公司 | Hydropyridopyrimidine derivative, preparation method therefor and medical use thereof |
CN113337602A (en) * | 2020-03-02 | 2021-09-03 | 苏州亚盛药业有限公司 | Methods of treatment and biomarkers for MDM2 inhibitors |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2302650A1 (en) * | 1997-09-08 | 1999-03-18 | William J. Ryan | Spiro¬pyrrolidine-2,3'-oxindole| compounds and methods of use |
US6979551B2 (en) | 2000-04-03 | 2005-12-27 | Rigel Pharmaceuticals, Inc. | Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents |
US6740495B1 (en) | 2000-04-03 | 2004-05-25 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase assay |
BR0215156A (en) | 2001-12-18 | 2004-10-19 | Hoffmann La Roche | Cis-imidazolines as mdm 2 inhibitors |
RU2305095C2 (en) | 2001-12-18 | 2007-08-27 | Ф.Хоффманн-Ля Рош Аг | Cis-2,4,5-triphenylimidazolines and pharmaceutical composition based on thereof |
US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
US7132421B2 (en) | 2003-06-17 | 2006-11-07 | Hoffmann-La Roche Inc. | CIS-imidazoles |
US20070111995A1 (en) | 2003-12-19 | 2007-05-17 | Allen David G | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors |
AU2005243465B2 (en) | 2004-05-18 | 2011-08-25 | F. Hoffmann-La Roche Ag | Novel CIS-imidazolines |
GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
CA2580621A1 (en) | 2004-09-24 | 2006-03-30 | Actelion Pharmaceuticals Ltd | New bicyclic antibiotics |
CN101160314B (en) * | 2005-02-22 | 2012-05-23 | 密执安州立大学董事会 | Small molecule inhibitors of mdm2 and the uses thereof |
US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
KR100939347B1 (en) | 2005-07-20 | 2010-01-29 | (주)카이로드 | Synthetic Method of optically pure S-3-hydroxypyrrolidine |
US20070213341A1 (en) | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
JP2009530236A (en) | 2006-03-13 | 2009-08-27 | エフ.ホフマン−ラ ロシュ アーゲー | Spiroindolinone derivatives |
CN101528223B (en) * | 2006-08-30 | 2013-05-01 | 密执安州立大学董事会 | New small molecule inhibitors of MDM2 and the uses thereof |
US7737174B2 (en) * | 2006-08-30 | 2010-06-15 | The Regents Of The University Of Michigan | Indole inhibitors of MDM2 and the uses thereof |
CA2662838A1 (en) | 2006-09-21 | 2008-03-27 | F. Hoffmann-La Roche Ag | Oxindole derivatives |
US7638548B2 (en) | 2006-11-09 | 2009-12-29 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
WO2008068171A1 (en) | 2006-12-08 | 2008-06-12 | F. Hoffmann-La Roche Ag | Substituted pyrimidines and their use as jnk modulators |
CA2682483A1 (en) | 2007-03-29 | 2008-10-09 | Novartis Ag | 3-imidazolyl-indoles for the treatment of proliferative diseases |
US7553833B2 (en) | 2007-05-17 | 2009-06-30 | Hoffmann-La Roche Inc. | 3,3-spiroindolinone derivatives |
US7834179B2 (en) | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
US8134001B2 (en) | 2007-12-14 | 2012-03-13 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
US7723372B2 (en) | 2008-03-19 | 2010-05-25 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
AR073578A1 (en) | 2008-09-15 | 2010-11-17 | Priaxon Ag | PIRROLIDIN-2-ONAS |
US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
PT2340021E (en) | 2008-09-18 | 2013-01-25 | Hoffmann La Roche | Substituted pyrrolidine-2-carboxamides |
AU2010205201A1 (en) | 2009-01-16 | 2011-08-04 | Daiichi Sankyo Company,Limited | Imidazothiazole derivative having proline ring structure |
US20100190814A1 (en) | 2009-01-26 | 2010-07-29 | Li Chen | Spiroindolinone derivative prodrugs |
US7928233B2 (en) | 2009-02-10 | 2011-04-19 | Hoffmann-La Roche Inc. | Spiroindolinone pyridine derivatives |
US8217051B2 (en) | 2009-02-17 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
US8017607B2 (en) | 2009-10-14 | 2011-09-13 | Hoffmann-La Roche Inc. | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions |
KR20120099462A (en) | 2009-11-12 | 2012-09-10 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Spiro-oxindole mdm2 antagonists |
US20110118283A1 (en) | 2009-11-17 | 2011-05-19 | Qingjie Ding | Substituted Pyrrolidine-2-Carboxamides |
US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
US8288431B2 (en) | 2010-02-17 | 2012-10-16 | Hoffmann-La Roche Inc. | Substituted spiroindolinones |
CA2800519A1 (en) | 2010-04-09 | 2011-10-13 | The Regents Of The University Of Michigan | Biomarkers for mdm2 inhibitors for use in treating disease |
US8217044B2 (en) | 2010-04-28 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone pyrrolidines |
US20120010235A1 (en) | 2010-07-12 | 2012-01-12 | Xin-Jie Chu | N-substituted pyrrolidines |
US20120046306A1 (en) | 2010-08-18 | 2012-02-23 | David Joseph Bartkovitz | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists |
US20120065210A1 (en) | 2010-09-15 | 2012-03-15 | Xin-Jie Chu | Substituted hexahydropyrrolo[1,2-c]imidazolones |
US20120071499A1 (en) | 2010-09-20 | 2012-03-22 | Xin-Jie Chu | Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones |
SG190230A1 (en) | 2010-11-12 | 2013-06-28 | Univ Michigan | Spiro-oxindole mdm2 antagonists |
WO2012076513A1 (en) | 2010-12-09 | 2012-06-14 | F. Hoffmann-La Roche Ag | 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer |
US8629133B2 (en) * | 2011-03-10 | 2014-01-14 | Daiichi Sankyo Company, Limited | Dispiropyrrolidine derivatives |
SG194873A1 (en) | 2011-05-11 | 2013-12-30 | Sanofi Sa | Spiro-oxindole mdm2 antagonists |
-
2012
- 2012-03-09 US US13/416,061 patent/US8629133B2/en active Active
- 2012-03-09 CN CN201280022149.9A patent/CN103635473B/en active Active
- 2012-03-09 DK DK12755073.9T patent/DK2684880T3/en active
- 2012-03-09 ES ES12755073.9T patent/ES2666870T3/en active Active
- 2012-03-09 KR KR1020137023609A patent/KR101779644B1/en active IP Right Grant
- 2012-03-09 HU HUE12755073A patent/HUE038714T2/en unknown
- 2012-03-09 CA CA2829188A patent/CA2829188C/en active Active
- 2012-03-09 RU RU2013145310A patent/RU2612534C2/en active
- 2012-03-09 RS RS20180472A patent/RS57158B1/en unknown
- 2012-03-09 SI SI201231253T patent/SI2684880T1/en unknown
- 2012-03-09 WO PCT/JP2012/056066 patent/WO2012121361A1/en active Application Filing
- 2012-03-09 SG SG10201601802YA patent/SG10201601802YA/en unknown
- 2012-03-09 JP JP2013503620A patent/JP5792279B2/en active Active
- 2012-03-09 LT LTEP12755073.9T patent/LT2684880T/en unknown
- 2012-03-09 TW TW101108003A patent/TWI494312B/en active
- 2012-03-09 CN CN201610086906.9A patent/CN105753872B/en active Active
- 2012-03-09 TR TR2018/07311T patent/TR201807311T4/en unknown
- 2012-03-09 SG SG2013065420A patent/SG193002A1/en unknown
- 2012-03-09 AU AU2012226890A patent/AU2012226890B2/en active Active
- 2012-03-09 PT PT127550739T patent/PT2684880T/en unknown
- 2012-03-09 EP EP12755073.9A patent/EP2684880B1/en active Active
- 2012-03-09 PL PL12755073T patent/PL2684880T3/en unknown
- 2012-03-09 MY MYPI2013003257A patent/MY172862A/en unknown
- 2012-03-09 MX MX2013010334A patent/MX342958B/en active IP Right Grant
- 2012-03-09 BR BR112013023175-0A patent/BR112013023175B1/en active IP Right Grant
-
2013
- 2013-08-30 ZA ZA2013/06552A patent/ZA201306552B/en unknown
- 2013-09-09 IL IL228322A patent/IL228322A/en active IP Right Grant
- 2013-10-09 CO CO13240487A patent/CO6781539A2/en active IP Right Grant
- 2013-11-14 US US14/080,589 patent/US20140121196A1/en not_active Abandoned
-
2015
- 2015-08-24 PH PH12015501860A patent/PH12015501860A1/en unknown
-
2018
- 2018-04-24 HR HRP20180646TT patent/HRP20180646T1/en unknown
-
2021
- 2021-04-19 US US17/234,404 patent/US20220106324A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2743432C2 (en) * | 2016-04-06 | 2021-02-18 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Mdm2 protein destructors |
US11192898B2 (en) | 2016-04-06 | 2021-12-07 | The Regents Of The University Of Michigan | MDM2 protein degraders |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2013145310A (en) | DISPYRO-PYRROLIDINE DERIVATIVES | |
TWI679201B (en) | Pyrazolopyrimidine compounds | |
RU2016140420A (en) | 1,3-BENZODIOXOL DERIVATIVE | |
RU2014130129A (en) | NEW PHOSPHATE COMPOUNDS, METHOD FOR PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
HRP20100561T1 (en) | Inhibitors of the interaction between mdm2 and p53 | |
IL274936B2 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
JP2008513532A5 (en) | ||
CN103327977B (en) | Dyscrasic treatment or prophylactic | |
JP2017528524A5 (en) | ||
RU2014130125A (en) | NEW PYROLIC COMPOUNDS, METHOD FOR PRODUCING THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
RU2014121205A (en) | ASOLES DERIVATIVES | |
JP2019530745A5 (en) | ||
WO2011141716A3 (en) | Modulators of chk-1 activity | |
RU2015118145A (en) | SUBSTITUTED BENZENE COMPOUNDS | |
RU2018101897A (en) | Bicyclic heterocyclic amide derivative | |
RU2012104700A (en) | ABABIQUE COMPOUND AND ITS SALT | |
AR086357A1 (en) | INDAZOL DERIVATIVES ACTIVE SUBSTITUTES AS QUINASE INHIBITORS | |
RU2011134283A (en) | IMIDAZOTIAZOZOLESE DERIVATIVES THAT HAVE A VALINE CYCLIC STRUCTURE | |
RU2011119525A (en) | MORPHOLINOPURINE DERIVATIVES | |
JP2011001339A5 (en) | ||
IN2014DN07283A (en) | ||
RU2015116749A (en) | MGLU2 / 3 antagonists for the treatment of autistic disorders | |
EA201391558A1 (en) | TETRAHYDROPYRAZOLO [1,5-A] Pyrimidine as an anti-tuberculosis compound | |
RU2011150250A (en) | HEDGEHOG ANTAGONISTS AND THEIR THERAPEUTIC APPLICATION | |
JP2020530020A (en) | A novel heterocyclic compound as a CDK8 / 19 inhibitor |